2025-04-10 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Review

**0) Executive Summary:**

UnitedHealth Group Inc. (UNH), a leading healthcare company, shows strong cumulative returns exceeding the S&P 500 (VOO) over the analyzed period.  However, recent price movements indicate high volatility and potential overvaluation, warranting careful consideration.  Earnings show recent strength but also volatility, and financial indicators display mixed signals regarding profitability and capital efficiency.

**1) Performance Comparison and Alpha/Beta Analysis:**

UNH, a diversified healthcare company, showed a cumulative return of 74.33% compared to the S&P 500's 66.94%, representing a difference of 7.4%. This places UNH in the 50.8th percentile of its historical performance relative to the S&P 500 based on the provided range (-38.8% to 52.2%).

The Alpha/Beta analysis reveals varying performance characteristics across different years.  While Alpha is generally positive, indicating outperformance, it fluctuates significantly, suggesting periods of both strong and weak relative performance. Beta, generally above 1, shows higher volatility than the market.  The significant CAGR variations and MDD (Maximum Drawdown) values further underline the inherent risk associated with UNH.  Capitalization (Cap) steadily increased, indicative of growth.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 64.0% | 56.1% | 35.0% | 0.1 | 181.0 |
| 2016-2018  | 55.0% | 63.9% | 37.0% | 0.2 | 207.3 |
| 2017-2019  | 41.0% | 63.9% | 11.0% | 0.3 | 248.8 |
| 2018-2020  | -20.0% | 63.9% | -45.0% | 0.5 | 301.7 |
| 2019-2021  | 34.0% | 60.8% | -20.0% | 0.6 | 438.0 |
| 2020-2022  | 28.0% | 67.1% | 22.0% | 0.6 | 468.4 |
| 2021-2023  | 35.0% | 67.6% | 18.0% | 0.4 | 472.1 |
| 2022-2024  | -27.0% | 68.8% | -44.0% | 0.3 | 460.8 |
| 2023-2025  | -3.0% | 73.2% | -18.0% | 0.2 | 529.2 |


**2) Recent Price Movement:**

* **Closing Price:** $578.5
* **5-Day Moving Average:** $544.35
* **20-Day Moving Average:** $518.80
* **60-Day Moving Average:** $512.13

The price is significantly above all moving averages, suggesting a recent surge. The sharp increase from the previous close ($553.08 to $578.5) indicates a rapid price jump (4.6%).


**3) Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.5289 (High Risk)
* **RSI:** 80.07 (Overbought)
* **PPO:** 1.043 (Positive momentum)
* **20-Day Relative Divergence Change:** +26.3% (Short-term uptrend)
* **Expected Return (2+ years):** 13.2% above S&P 500.

The high RSI and MRI values suggest the stock is overbought and carries significant risk.  The positive PPO and relative divergence indicate a short-term uptrend, but the overall picture points to potential overvaluation. The expected return is high but needs to be weighed against the risks indicated by other factors.


**4) Recent Earnings Analysis:**

The earnings data shows significant fluctuation in EPS and consistent revenue growth.  The large negative EPS in Q2 2024 is a major concern and requires further investigation.

| Date       | EPS   | Revenue        |
|------------|-------|----------------|
| 2024-11-04 | 6.56  | $100.82 B      |
| 2024-08-09 | 4.58  | $98.86 B       |
| 2024-05-09 | -1.53 | $99.80 B       |
| 2023-11-06 | 6.31  | $92.36 B       |
| 2024-11-04 | 6.31  | $92.36 B       | *(Duplicate Data)*


**5) Financial Information:**

Revenue shows consistent growth, while profit margins have been relatively stable, showing some minor fluctuation. ROE is highly volatile, indicating fluctuating profitability and potentially inefficient capital utilization.  The negative ROE in Q1 2024 raises serious concern.

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $100.81B   | 21.14%        |
| 2024-09-30 | $100.82B   | 22.84%        |
| 2024-06-30 | $98.86B    | 22.31%        |
| 2024-03-31 | $99.80B    | 23.05%        |
| 2023-12-31 | $94.43B    | 23.30%        |


**Capital and Profitability:**

| Quarter | Equity      | ROE    |
|---------|-------------|--------|
| 2024-12-31 | $92.66B    | 5.98%  |
| 2024-09-30 | $94.53B    | 6.41%  |
| 2024-06-30 | $89.36B    | 4.72%  |
| 2024-03-31 | $86.69B    | -1.63% |
| 2023-12-31 | $88.76B    | 6.15%  |


**6) Overall Analysis:**

UNH has shown strong cumulative returns exceeding the S&P 500, but the recent price surge, coupled with high RSI and MRI, suggests a high degree of overvaluation and risk.  The earnings data exhibits volatility, and financial indicators present a mixed picture of profitability and capital efficiency. The negative EPS and ROE in Q1 2024 are significant red flags requiring further investigation.  While the long-term expected return is positive, the high short-term risk necessitates careful consideration before investing.  Further analysis, including a deeper dive into the Q2 2024 loss and an assessment of future growth prospects, is recommended before making any investment decisions.
